New hope for advanced prostate cancer: drug may replace hormone therapy
NCT ID NCT06574880
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tests whether adding the drug Pluvicto to standard radiation can lower the chance of prostate cancer coming back while avoiding the side effects of long-term hormone therapy. About 45 adults with advanced local prostate cancer will receive one or two doses of Pluvicto before and after radiation. The goal is to find the safest dose and see if this approach helps men stay cancer-free without needing hormone therapy for at least three years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF PROSTATE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.